Treatment of Bullous Systemic Lupus Erythematosus

  • L. D
  • L. C
  • S. Z
  • et al.
Citations of this article
Mendeley users who have this article in their library.


Bullous systemic lupus erythematosus (BSLE) is an autoantibody-mediated vesiculobullous disease in patients with SLE. Autoimmunity in BSLE is characterized by the presence of circulating anti-type VII collagen antibodies. BSLE patients often present with multiple, tense, clear fluid-filled vesicles and bullae overlying erythematous edematous plaques. Skin biopsy from BSLE patients shows subepidermal bullae with numerous neutrophils and only occasional eosinophils. Furthermore, immunofluorescence examination showed linear deposition of lgG, lgA, C3, and C1q along the basement membrane zone. BSLE patients with corticosteroids treatment constantly do not receive a marked improvement, while dapsone generally dramatically improved the skin condition. Recently, it has been reported that quite a few cases of BSLE were successfully treated with other immune suppressive drugs. Therefore, a comprehensive review of the treatment of BSLE would be beneficial to cure the disease.




L., D., L., C., S., Z., Y., W., Y., H., Y., H., … Shi G.  AO  - Duan, L. O. (2015). Treatment of Bullous Systemic Lupus Erythematosus. Journal of Immunology Research. L. Duan, Department of Rheumatology and Clinical Immunology, Xiamen University, Xiamen 361003, China: Hindawi Publishing Corporation (410 Park Avenue, 15th Floor, 287 pmb, New York NY 10022, United States). Retrieved from

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free